Abbott Laboratories (ABT) saw better trading amidst speculations of an impressive earnings report. The financial advisory firms Toth Financial, Cyndeo Wealth Partners LLC, Linden, Thomas, and Paradiem LLC, among others, have increased their stake in Abbott Laboratories. Meanwhile, It has been issuing 2025 sales guidance and is projected to outperform other medical stocks in 2025. The stock price is expected to rise according to Wells Fargo, Stifel Nicolaus, and UBS Group, although recent Q4 sales were lower than expected. Both Wells Fargo and Stifel Nicolaus set new higher price targets for the company. Rep. Thomas H.Keann, Jr purchased an undisclosed number of Abbott shares, indicating confidence in the firm. Another highlight lie in the device demand driving Abbott's 2025 profit forecast meeting estimates. However, the company has also seen a drop in worldwide COVID-19 testing sales, which has contributed to a lag in Q1 profit guidance, leading to a dip in the pre-market stock. Despite this, different wealth management firms have been buying shares, making it a trending stock. Finally, Abbott stock trades at a discounted P/B value, a fact that investors find appealing.
Abbott Laboratories ABT News Analytics from Mon, 16 Sep 2024 07:00:00 GMT to Sat, 25 Jan 2025 14:19:48 GMT -
Rating 5
- Innovation 0
- Information 6
- Rumor -1
